Global Value Dossier

Product Overview

TheraPlus® - Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)

New data available: Updated survival analysis from Phase 3 trial now available in Clinical Evidence section.

Target Population

125,000

Response Rate

42%

Cost per QALY

$45,000

HTA Approvals

8/12

Quick Access

Clinical Evidence

Economic Models

HTA Submissions

Payer Resources

Recent Updates

View All

NICE Final Appraisal Determination Received

Positive recommendation for TheraPlus in advanced NSCLC

2 hours ago

Updated Budget Impact Model

New model incorporating real-world adherence data

1 day ago

Real-World Evidence Study Published

Analysis of 1,200 patients shows improved outcomes

3 days ago

Evidence Highlights

Phase 3 Trial Results

Clinical

Significant improvement in progression-free survival compared to standard of care (HR 0.65; 95% CI 0.52-0.81; p<0.001)

NEJM 2023; 389:123-134 View Details

Cost-Effectiveness Analysis

Economic

TheraPlus demonstrated cost-effectiveness with ICER of $45,000/QALY, below commonly accepted thresholds

PharmacoEconomics 2023 View Model

Disease Landscape: Non-Small Cell Lung Cancer

Global Epidemiology

Hover over points for country data

Global Incidence (Annual)

2.2 Million

5-Year Survival

23%

Burden of Illness

Diagnosis to Treatment 42 days

Hospitalizations/Year 3.2

Monthly Treatment Cost $12,500

QoL Impact (0-100) 52

Unmet Needs

Improved treatment options for EGFR-negative patients
Reduced toxicity profiles
Longer progression-free survival

Patient Experience

John D., 62

Diagnosed 2019, Stage IV NSCLC

"The fatigue from previous treatments made it impossible to work. With TheraPlus, I've been able to return to part-time work and enjoy time with my grandchildren."

Treatment duration: 14 months Full Story

Maria L., 58

Diagnosed 2021, Stage IIIB NSCLC

"I experienced severe nausea with my previous treatment. Switching to TheraPlus reduced my side effects significantly and improved my quality of life."

Treatment duration: 9 months Full Story

Clinical Evidence

Key Clinical Trials

THERA-003: Pivotal Phase 3 Trial

Published

Randomized, double-blind study of TheraPlus vs chemotherapy in 450 patients with advanced NSCLC

n=450 24 months PFS Primary Endpoint

THERA-005: Combination Therapy Study

Interim Analysis

Phase 2 study evaluating TheraPlus + pembrolizumab in 120 patients

n=120 18 months ORR Primary Endpoint

THERA-007: Subgroup Analysis

Post-hoc

Analysis of elderly population (≥75 years) from THERA-003

n=85 Safety Focus

Efficacy Summary

Progression-Free Survival (PFS)

9.8 mo

6.2 mo

TheraPlus Standard of Care

Overall Response Rate (ORR)

42%

28%

TheraPlus Standard of Care

Grade 3+ Adverse Events

22%

38%

TheraPlus Standard of Care

Safety Profile

Adverse Events ≥10%

Fatigue 32%

Nausea 28%

Rash 25%

Diarrhea 18%

Serious Adverse Events

Pneumonitis 4%

Hepatotoxicity 3%

Cardiac Events 2%

Discontinuation Rate

8%

due to adverse events

Economic Evidence

Interactive cost-effectiveness models and budget impact analysis

Global Value Story

Core value proposition and evidence-linked claims

HTA & Reimbursement

HTA outcomes and reimbursement resources